ZANGRANDO, ANDREA
ZANGRANDO, ANDREA
An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer.
2015 Agostini, Marco; Janssen, Klaus Peter; Kim, Il Jin; D'Angelo, Edoardo; Pizzini, Silvia; Zangrando, Andrea; Zanon, Carlo; Pastrello, Chiara; Maretto, Isacco; Digito, Maura; Bedin, Chiara; Jurisica, Igor; Rizzolio, Flavio; Giordano, Antonio; Bortoluzzi, Stefania; Nitti, Donato; Pucciarelli, Salvatore
CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript
2021 Zangrando, A.; Cavagnero, F.; Scarparo, P.; Varotto, E.; Francescato, S.; Tregnago, C.; Cuccurullo, R.; Fagioli, F.; Nigro, L. L.; Masetti, R.; Putti, M. C.; Rizzari, C.; Santoro, N.; Pession, A.; Pigazzi, M.; Locatelli, F.; Basso, G.; Buldini, B.
Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia
2019 Gabelli, Maria; Disaro', Silvia; Scarparo, Pamela; Francescato, Samuela; Zangrando, Andrea; Valsecchi, M Grazia; Putti, M Caterina; Basso, Giuseppe; Buldini, Barbara
Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.
2010 Bresolin, Silvia; Zecca, M; Flotho, C; Trentin, Luca; Zangrando, Andrea; Sainati, Laura; Stary, J; de Moerloose, B; Hasle, H; Niemeyer, Cm; TE KRONNIE, Geertrudy; Locatelli, F; Basso, Giuseppe
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease
2021 Mikhailova, E.; Semchenkova, A.; Illarionova, O.; Kashpor, S.; Brilliantova, V.; Zakharova, E.; Zerkalenkova, E.; Zangrando, A.; Bocharova, N.; Shelikhova, L.; Diakonova, Y.; Zhogov, V.; Khismatullina, R.; Molostova, O.; Buldini, B.; Raykina, E.; Larin, S.; Olshanskaya, Y.; Miakova, N.; Novichkova, G.; Maschan, M.; Popov, A. M.